Nutra Pharma Corp (NPHC)
| Market Cap | 715.97K+0.0% |
| Revenue (ttm) | n/a-42.2% |
| Net Income | n/a-315.8% |
| EPS | n/a-204.2% |
| Shares Out | 7.16B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,000 |
| Open | 0.00 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 0.01 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About NPHC
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, overthecounter pain reliever to treat moderate to severe chronic pain in companion animals; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxury Feet, an OTC pain reliever for foot pain from high heels and stilettos. It is also involved in developing RPI-78M to treat neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, and general anti -viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Boca Raton, Florida.
$NPHC stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NPHC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NPHC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NPHC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NPHC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NPHC from public contracts
Source: USAspending.gov
NPHC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NPHC’s recent data — informational, not investment advice
